DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-871

Warner Chilcott (US), Inc.
Attention: Alvin D. Howard
Vice President, Regulatory Affairs
100 Enterprise Drive
Rockaway, NJ 07866

Dear Mr. Howard:

Please refer to your new drug application (NDA) dated April 15, 2005, received April 18, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Loestrin® 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate) Tablets.

We acknowledge receipt of your submissions dated July 28, August 11, October 5 and 12, December 7 and 13, 2005; January 18 and 24, February 1, 2, 3, 6, 9, 10, 14, 16, and 17, 2006.

This new drug application provides for the use of Loestrin® 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate) Tablets for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the physician package insert and patient package insert, and immediate container and carton labels submitted February 16, 2006. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-871**." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Reproductive and Urologic Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Karen Kirchberg, R.N., Regulatory Health Project Manager, at (301) 796-2130.

Sincerely,

{See appended electronic signature page}

Daniel Shames, M.D.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Daniel A. Shames

2/17/2006 04:48:25 PM